SPY319.34+7.98 2.56%
DIA271.55+8.22 3.12%
IXIC9,811.09+195.28 2.03%

Needham Maintains Buy on Cantel Medical, Lowers Price Target to $65

Needham analyst Mike Matson maintains Cantel Medical (NYSE:CMD) with a Buy and lowers the price target from $75 to $65.

Benzinga · 05/12/2020 16:34

Needham analyst Mike Matson maintains Cantel Medical (NYSE:CMD) with a Buy and lowers the price target from $75 to $65.